Search

Displaying results 5271 - 5280 of 6198 in total
  1. Drug

    Prosetin

    go.drugbank.com/drugs/DB18649
    Investigational

    Prosetin is an orally administered blocker of MAP4K under investigation for the treatment of amyotrophic lateral sclerosis.[L48360]

  2. Drug

    Rovaleucel

    go.drugbank.com/drugs/DB18691
    Investigational

    Rovaleucel is an EBV-specific autologous T-cell therapy under investigation for the treatment of EBV-positive cancers.

  3. Drug

    Autologous DNP-conjugated tumour vaccine

    go.drugbank.com/drugs/DB17361
    Investigational

    Autologous DNP-conjugated tumour vaccine, or melanoma vaccine, is an investigational autologous cell vaccine technology for melanoma.[A254806]

  4. Drug

    Trotabresib

    go.drugbank.com/drugs/DB17421
    Investigational

    Trotabresib is an oral, potent, and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.

  5. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

  6. Drug

    Brazikumab

    go.drugbank.com/drugs/DB16115
    Investigational

    Brazikumab is under investigation in clinical trial NCT03759288 (An Active and Placebo-controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease).

  7. Drug

    Foralumab

    go.drugbank.com/drugs/DB16170
    Investigational

    Foralumab is under investigation in clinical trial NCT03291249 (Assessment of the Safety of Foralumab, an Oral Anti-cd3 Antibody, in Patients With NASH and T2DM).

  8. Drug

    Dihydroxyacetone phosphate

    go.drugbank.com/drugs/DB04326
    Investigational

    Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.

  9. Drug

    Fleroxacin

    go.drugbank.com/drugs/DB04576
    Experimental

    Fleroxacin is not an inhibitor of CYP1A2.[A39048]

  10. Drug

    JSM 6427

    go.drugbank.com/drugs/DB06139
    Investigational

    JSM 6427 is the first small molecule alpha5beta1 integrin receptor antagonist of its kind to be developed. It has been biologically validated for therapeutic use in the prevention and treatment of wet AMD, the leading cause of blindness ...